CJC-1295 (No DAC) / GHRP-6Explore study findings
Why a two-peptide challenge gave different results across groups
2 numbered sourcesSource years 2005, 2024
Peptides are short amino-acid chains held together by peptide bonds. Some can temporarily stimulate the release of a hormone, giving researchers a way to study how responsive a gland is. CJC-1295 (No DAC) / GHRP-6 combines a label for modified growth hormone–releasing factor (1–29) with GHRP-6, a ghrelin-receptor agonist. What would it take to interpret a response across people with different baseline characteristics? [1, 2]
No recent primary study tested the exact catalog combination for this purpose. An older study used growth hormone–releasing hormone (GHRH) and GHRP-6 as a combined challenge. The researchers compared a small group of men with severe obesity, a group of older men, and a healthy comparison group. They measured blood growth hormone (GH) repeatedly after the challenge. The men with severe obesity had lower average peak and cumulative GH responses than the healthy comparison group. The difference between the older men and controls was less clear in this small sample. [2]
The researchers asked whether the same threshold could indicate GH deficiency across those groups. Several men with severe obesity had responses below the threshold under consideration. The study demonstrates how baseline physiology can influence the result of a stimulation test, even when the laboratory measures the same hormone and the experimental stimulus is the same. [2]
The challenge involved GHRH, while the catalog label describes a modified 29-residue analogue. The older results apply to the tested molecules and participants. They cannot validate a diagnostic threshold for the no-DAC and GHRP-6 mixture. They do show why studies that compare responses across populations need to describe who was included and how a threshold was evaluated. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
